Treatable Conditions

Patient Selection Indications

  • Stable or Unstable Angina
  • Heart Attack – Acute Myocardial Infarction
  • Cardiogenic Shock
  • Congestive Heart Failure
  • Patients with anginal equivalent symptoms, for example dyspenea or fatigue related to ischemia
  • Patients with ischemic Cardiomyopathy including those with EF< 35% that are medically compensated
  • The elderly, diabetics and small females
  • Those with unsuitable coronary anatomy: small, diffuse and/or distal vessel disease
  • Prior failed revascularization
  • Renal insufficiency
  • Compromised CNS circulation or those receiving steroid therapies
  • Patients with moderate to severe angina who cannot tolerate medical therapy
  • Patients with Prinzmental Angina class III or IV symptoms despite medical therapy
  • Patients whose quality of life is significantly impaired and who have become sedentary due to fear including angina attacks
  • Patients taking excessive nitrates

Other Treatable Conditions

The FDA has granted the RejuvaHeart™ protocol clearance for treating a variety of conditions including the following:

  • Aortic Insufficiency
  • Arrhythmia
  • Erectile Dysfunction
  • Diabetic
  • Fatigue/Malaise
  • Heart Failure
  • Hepato-Renal Syndrome
  • Hypertension
  • Peripheral Vascular Disease or Phlebitis
  • Restless Leg Syndrome
  • Retinal Artery Occlusion
  • Rotational Vertebro-Basilar Insufficiency
  • Stroke
  • Sudden Deafness
  • Tinnitus
  • Unstable Angina


According to current FDA labeling, RejuvaHeart™ Therapy should not be used for treating patients with:

  • Arrhythmias that interfere with machine triggering
  • Bleeding diathesis
  • Active thrombophlebitis
  • Severe lower extremity vaso-occlusive disease
  • Presence of a documented aortic aneurysm requiring surgical repair
  • Pregnancy